Shopping Cart
- Remove All
- Your shopping cart is currently empty
Nevanimibe is an orally active and selective inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) (EC50 of 9 nM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 1-2 weeks | |
50 mg | $1,980 | 1-2 weeks | |
100 mg | $2,500 | 1-2 weeks |
Description | Nevanimibe is an orally active and selective inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) (EC50 of 9 nM). |
Targets&IC50 | ACAT2:368 nM (EC50), ACAT1:9 nM (EC50) |
In vitro | In H295R human adrenocortical carcinoma cells, Nevanimibe(ATR-101) decreases the formation of cholesteryl esters and increases FC levels, demonstrating potent inhibition of ACAT1 activity.?Caspase-3/7 levels and terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate nick end labeled-positive cells are increased by ATR-101 treatment, indicating activation of apoptosis[1]. |
Alias | PD-132301, ATR-101 |
Molecular Weight | 421.62 |
Formula | C27H39N3O |
Cas No. | 133825-80-6 |
Relative Density. | 1.062 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.